Latest Ratings for CRSP DateFirmActionFromTo Feb 2022RBC CapitalMaintainsSector Perform Feb 2022SVB ...
CRSP reports wider-than-expected first-quarter loss. Revenues also miss estimates. Stock tanks 12%....
CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene ed...
Just because a business does not make any money, does not mean that the stock will go down. For exam...
CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has received a consensus recommendation of “H...